The intent of this Lab Talk is to raise awareness on the evolution of HER2 assessment in Breast cancer. The way HER2 results are interpreted at the lower end of the spectrum has become increasingly important as recent studies demonstrate the significance of differentiating low range cases. As new therapies emerge the laboratories performing HER2 must be prepared for a new standard of assessment in order for best patient outcomes.
Date and time: Thursday September 22nd, 2022 12pm (ET)
Duration: 1 hour (total)
• Welcome, Introduction to DXRX [5mins]
• The Evolution of HER2 Assessment in the Treatment of Breast Cancer [45mins]
• Discussion and Q&A [10 mins]
Note: This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology (ASCP) as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program and any other boards that recognize this credit.
We are in the process of uploading this recording.
Speaker name: Dr. David Hicks, MD
Speaker title: Director of the IHC/ISH Laboratory and Chief of the Breast Subspecialty Service at the University of Rochester Medical Center
David G. Hicks, MD, is currently the director of the IHC/ISH Laboratory and Chief of the Breast Subspecialty Service at the University of Rochester Medical Center.Dr. Hicks is a western New York native and earned his medical degree from the University of Rochester School of Medicine and Dentistry. His postgraduate training includes an internship in internal medicine and a residency in anatomic pathology at the Hospital of the University of Pennsylvania in Philadelphia.
Dr. Hicks' innovative approaches to improving efficiency and quality in surgical pathology have been highlighted in publications and invited lectures sponsored by national pathology organizations. His organizational interests are in the development of a subspecialty-based surgical pathology system, combining disease-specific diagnostic and prognostic expertise with translational research based on organ systems and disease categories.
Dr. Hick’s current research interests focuses on the molecular genetic profiling of clinical samples from patients with cancer.Much of his recent work has involved a search for new molecular genetic markers to help better understand the prognosis and guide therapeutic management of breast cancer. Dr. Hicks has co-authored over 180 peer reviewed articles that have appeared in a variety of Journals and is also the author of a popular Breast Pathology textbook published by Elsevier.He also served as a member of the ASCO/CAP consensus panel for both the ER/PR and HER2 testing guidelines.Dr. Hicks is active in both the CAP and the USCAP and has presented numerous workshops and platform presentations for both organizations.